FDA Issues CRL for Patisiran in Treatment of ATTR Cardiomyop

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.

Related Keywords

Oregon , United States , Kunzmannk Patisiran , Campbellp Patisiran , Ahmad Masri , Christopher Oconnor , Yvonne Greenstreet , Alnylam Pharmaceuticals , Investor Relations Alnylam Pharmaceuticals Inc , Oregon Health , Renal Drugs Advisory Committee , Vascular Institute , Hypertrophic Cardiomyopathy Center , Drug Administration , Sciences University , Complete Response Letter , Chief Executive Officer , Annual Congress , Heart Failure Association , European Society , New Drug Application , Christophero Connor , Inova Heart , Supplemental New Drug Application , Patisiran , Onpattro , Patisiran Onpattro , Attr Cm , Cardiomyopathy , Patisiran In Cardiomyopathy , Patisiran For Cardiomyopathy ,